As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

But during tumour formation, the cancer cells can end up with only the faulty gene. "In cancer cells it is common that larger or smaller parts the chromosomes are lost. If the faulty gene variant is ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, ...

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Researchers have created a groundbreaking antibody that combines targeting, delivery, and immune activation to treat cancer, ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...